Range of suitable clients: CDEC discussed the uncertainty in the volume of individuals with moderately severe to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people who're categorised as possessing delicate or average disease could have a significant bleeding phenotype, which https://hemgenix31593.imblogs.net/85484481/5-tips-about-hemgenix-you-can-use-today